Mingyuan Medicare Development
Mingyuan Medicare Development is a Bermuda-incorporated, Hong Kong-headquartered investment company that historically focused on biomedical businesses in mainland China.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Mingyuan Medicare Development Co., Ltd. was a Bermuda-incorporated investment company headquartered in Hong Kong. The entity was formerly known as Sing Tao Holdings Limited and later Shanghai Ming Yuan Holdings Limited before adopting the Mingyuan Medicare Development name. Although its corporate domicile and listed-company infrastructure were associated with Bermuda and Hong Kong, its principal business activity during much of its later history was concentrated in mainland China, where it acquired interests in biomedical and healthcare-related companies. The company became a public-company vehicle under the control of Ming Yuan Investment Group after the group acquired Sing Tao Holdings in August 2002. The transaction involved a cash-shell-style listed entity and was followed by a change of name to Shanghai Ming Yuan Holdings in October 2002. The company subsequently pursued acquisitions of mainland Chinese biomedical businesses, including businesses connected with the interests of its largest shareholder, Yao Yuan. This made the company less a consumer-facing healthcare brand than a listed investment and holding platform. Its corporate history was also closely associated with governance disputes, financial-reporting failures, shareholder conflict and regulatory intervention. Mingyuan did not publish its annual reports for the 2014, 2015 and 2016 financial years within the expected periods. Trading in its shares was suspended in 2015 after the delayed 2014 annual report. At around the same time, shares pledged by Ming Yuan Investment Group to a creditor were reportedly sold to other investors in connection with a loan dispute, leading to litigation by the investment group. A change in shareholder control followed. Andrew Lam Ping-cheung, described in the company’s history as the new largest shareholder, obtained a court order from the Supreme Court of Bermuda that enabled the 2016 annual general meeting to proceed. Lam and his allies successfully re-elected the company’s board, replacing the previous board associated with Yao Yuan and other directors. The incoming board reported suspected asset diversion and irregularities in prior financial statements. It also reported that the company’s Hong Kong office was missing a hard drive and corporate stamp immediately after the change in directorship. The Hong Kong Stock Exchange Listing Committee censured former directors in September 2016 in connection with a payment of approximately CNY396 million made in December 2013 by a subsidiary to Beijing Nong Long Investment Management for an alleged foreign-exchange service. The funds were reportedly unaccounted for despite claims that they had been recovered. Mingyuan later sued Deloitte’s Hong Kong practice, alleging that the auditor had failed to detect, suspect or report fraudulent activity and other irregularities. A forensic investigation commissioned by the company reportedly raised questions about an alleged Agricultural Bank of China account said to contain approximately CNY420 million, stating that the relevant subsidiary did not appear to have such an account. In October 2017, Hong Kong’s Securities and Futures Commission directed the Stock Exchange of Hong Kong to suspend all dealings in the company’s shares. The regulator’s concerns reportedly included false, incomplete or misleading information in the 2013 annual report and other company announcements prepared under the former management. Mingyuan was ultimately delisted from the Hong Kong Stock Exchange in January 2020. Public reference material does not establish a current operating business, active listing, present ownership structure or current corporate website, so its present status should be treated as uncertain.
History
Mingyuan Medicare Development traces its listed-company identity to Sing Tao Holdings Limited, a Bermuda-incorporated company associated with Hong Kong. In August 2002, Ming Yuan Investment Group, owned by Chinese businessman Yao Yuan, acquired Sing Tao Holdings. The listed vehicle was renamed Shanghai Ming Yuan Holdings in October of that year. The transaction separated the listed company from the group’s principal newspaper business, which continued under Sing Tao Media Holdings, and from a hotel in Canada. After the acquisition, the company used its listed-company platform to pursue investments and acquisitions in biomedical businesses located in mainland China. Several of these businesses were associated with, or connected to, the interests of the controlling shareholder. The company therefore operated primarily as a corporate investment and healthcare-related holding vehicle rather than as a conventional medical-services or consumer-products brand. Its registered domicile remained Bermuda and its headquarters were in Hong Kong, while its operational focus was largely mainland Chinese. In 2012, Mingyuan was removed from the MSCI China Index’s Global Small Cap Indices. The company’s later history was dominated by reporting delays and a breakdown in market trading. It failed to publish annual reports for the 2014, 2015 and 2016 financial years. When the 2014 report was not issued on schedule in mid-2015, trading in its shares was suspended. The suspension became prolonged, and the company’s ability to maintain a normally functioning listed-company structure was increasingly challenged. A related dispute concerned shares pledged by Ming Yuan Investment Group to a creditor. The creditor sold the pledged shares to other investors in an effort to refinance or recover the related loan. Ming Yuan Investment Group subsequently sued the creditor. This ownership conflict contributed to a contest for control of the company and its board. Andrew Lam Ping-cheung emerged as the new largest shareholder and sought to convene the 2016 annual general meeting. The Supreme Court of Bermuda issued an order that enabled the meeting to proceed. Lam’s side successfully re-elected the entire board, displacing the previous board on which Yao Yuan had served. Following the handover, the incoming directors reported suspected removal or diversion of company assets and irregularities in earlier financial statements. They also reported that a hard drive and the company stamp were missing from its Hong Kong office immediately after the change in directorship. The Hong Kong Stock Exchange Listing Committee later censured former directors Yao Yuan, Zhao Chao, Zhou Li Qun, Yu Ti Jun, Lee Sze Ho and Tang Yan Qin. The disciplinary findings included a payment of approximately CNY396 million made by a subsidiary on 23 December 2013 to Beijing Nong Long Investment Management for an alleged foreign-exchange service. The money was reportedly missing, even though it had purportedly been recovered. A forensic investigator engaged by the company also reportedly found that the subsidiary did not have the Agricultural Bank of China account said to contain approximately CNY420 million in recovered funds. In December 2016, Mingyuan sued Deloitte’s Hong Kong practice. The company alleged that the auditor had failed to detect, suspect or report fraudulent conduct and other irregularities by the former management. The available reference material does not establish the final outcome of that litigation. In October 2017, Hong Kong’s Securities and Futures Commission directed the Stock Exchange of Hong Kong to suspend all dealings in Mingyuan’s shares. The stated concerns included information in the 2013 annual report and several company announcements that was allegedly false, incomplete or misleading. The material indicated that the documents had been prepared by the former management and that none of the former board members remained on the board at the time of the regulatory action. Mingyuan was delisted from the Hong Kong Stock Exchange in January 2020. Publicly available reference material does not provide a reliable account of its post-delisting operations, ownership, management or continuing business activities. The company’s current status is consequently uncertain.
- 2020
Hong Kong listing terminated
[1]Mingyuan was delisted from the Hong Kong Stock Exchange.
- 2017
Securities regulator orders continued suspension
[1]Hong Kong’s Securities and Futures Commission directed the Stock Exchange to suspend all dealings in the shares.
- 2016
Court-backed board change
[1]A Bermuda court order enabled the 2016 annual general meeting, after which Andrew Lam’s shareholder group re-elected the board.
- 2016
Former directors censured
[1]The Hong Kong Stock Exchange Listing Committee censured six former directors over governance, disclosure and alleged asset-related matters.
- 2015
Trading suspension begins
[1]Trading was suspended after the company failed to publish its 2014 annual report on time.
- 2012
Removed from MSCI China small-cap indices
[1]Mingyuan was removed from MSCI China’s Global Small Cap Indices.
- 2002
Ming Yuan Investment Group acquires Sing Tao Holdings
[1]Ming Yuan Investment Group acquired the listed Sing Tao Holdings vehicle in August.
- 2002
Listed company renamed Shanghai Ming Yuan Holdings
[1]The acquired company changed its name to Shanghai Ming Yuan Holdings in October and began pursuing mainland Chinese biomedical investments.
- 2001
Sing Tao Holdings acquired by Global China Technology Group
[1]Global China Technology Group acquired Sing Tao Holdings before the company was subsequently sold to Ming Yuan Investment Group.
Products and positioning
A listed investment and holding platform focused historically on biomedical businesses and other mainland Chinese corporate assets rather than a consumer healthcare product brand.
Healthcare investment
Biomedical investment portfolio
The company’s principal historical business consisted of acquiring and holding interests in biomedical firms based in mainland China. Public reference material identifies this investment focus but does not provide a complete, reliable list of product names, brands or operating subsidiaries.
Corporate holding structure · 2002
Listed investment vehicle
Mingyuan functioned as a public-company platform through which its controlling investment group pursued acquisitions and corporate investments. It was not primarily a retail medical-products brand and did not have a documented flagship consumer offering.
Controversies
2017
Regulatory concerns over company disclosures
The Securities and Futures Commission cited concerns that the 2013 annual report and several announcements contained false, incomplete or misleading information prepared under the former management.
2016
Alleged missing funds and former-management irregularities
Following a board change, the incoming directors reported suspected asset diversion and irregularities in earlier financial statements. The reported issues included a CNY396 million payment to Beijing Nong Long Investment Management for an alleged foreign-exchange service and questions surrounding an alleged CNY420 million recovery account.
2016
Corporate records and property reported missing
After the change in directorship, the company reported that a hard drive and its corporate stamp were missing from the Hong Kong office.
Brand decisions
2016
Replace the board after shareholder challengeOtherBackground
A shareholder-control dispute followed the reported sale of pledged shares and litigation involving Ming Yuan Investment Group and a creditor.
Action taken
Andrew Lam Ping-cheung secured a Bermuda court order allowing the annual general meeting to proceed, and his shareholder group re-elected the board.
Aftermath
The new board investigated the former management, reported suspected irregularities and pursued legal and regulatory remedies.
2015
Suspend trading while annual reporting remained incompleteStrategyBackground
The company failed to publish its 2014 annual report within the required period.
Action taken
Trading in the company’s shares was suspended, and the suspension continued through subsequent reporting and governance disputes.
Aftermath
The prolonged suspension was followed by regulatory action and eventual delisting in 2020.
2002
Acquire and repurpose Sing Tao HoldingsM&ABackground
Ming Yuan Investment Group acquired Sing Tao Holdings as a listed corporate vehicle after the business had previously been acquired by Global China Technology Group.
Action taken
The group acquired the company, renamed it Shanghai Ming Yuan Holdings and redirected its strategic focus toward mainland Chinese biomedical investments.
Aftermath
The listed entity became an investment platform for healthcare and biomedical acquisitions, separate from the newspaper and Canadian hotel assets excluded from the transaction.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/mingyuan-medicare-development · Editorial policy · How profiles are compiled